Scarica l'app Stockscreener
0.6225
0.47%
0.0029
Dopo l'orario di chiusura:
.63
0.0075
+1.20%
InspireMD Inc. Borsa (NSPR) Ultime notizie
InspireMD (NASDAQ:NSPR) Will Have To Spend Its Cash Wisely - Simply Wall Street
Form 4 InspireMD Inc For: 27 September By Investing.com - Investing.com UK
Form 4 InspireMD Inc For: 26 September By Investing.com - Investing.com Nigeria
Inspiremd Stock Price Forecast. Should You Buy NSPR? - StockInvest.us
Price performance - Yahoo Finance Singapore
Director Stuka Paul reports acquiring and disposing of two warrant series at InspireMD (NSPR). - Stock Titan
InspireMD (NSPR) director Gary S. Roubin acquired and disposed of warrants with different exercise prices. - Stock Titan
InspireMD (NSPR) director Michael Berman reports acquiring and disposing of warrants at two exercise prices. - Stock Titan
InspireMD amends certain Series J, Series K warrants - Medical Buyer
Lake Street Maintains InspireMD(NSPR.US) With Buy Rating, Maintains Target Price $4 - Moomoo
InspireMD (NASDAQ: NSPR) Revises Series J and K Warrants with $0.7674 Exercise Price and FDA-Linked Expiry by May 2028 - Kalkine Media
InspireMD Amends Warrants for Up to $11 Million Tied to FDA Approval - Minichart
InspireMD amends warrants tied to FDA approval timeline By Investing.com - Investing.com South Africa
InspireMD Amends Warrants to Support CGuard Prime Launch - TipRanks
InspireMD amends warrants tied to FDA approval timeline - Investing.com
InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million - The Manila Times
An anticipated FDA approval could open up $11 million for InspireMD's stroke-prevention device. - Stock Titan
InspireMD Q2FY26 Results: Net loss widens to $14.3M on recall impact - scanx.trade
Full Transcript: InspireMD Q2 2026 Earnings Call - Benzinga
NSPR: Innovative carotid stent technology is set to disrupt a rapidly expanding U.S. vascular market - TradingView
InspireMD announces inducement grants - Medical Buyer
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
InspireMD Inc. (NSPR) Key Financial Ratios – Valuation, Profitability & More - Value Research
InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
InspireMD Inc. (NSPR) Peer Comparison – Compare with Others - valueresearchonline.com
InspireMD Inc. Series B Warrants (NSPRZ) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
InspireMD Inc (NSPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
InspireMD Inc. Series B Warrants (NSPRZ) Peer Comparison – Compare with Others - Value Research
InspireMD Earnings Call: Recall Pain, Regulatory Potential - TipRanks
InspireMD Inc. Series B Warrants (NSPRZ) Key Financial Ratios – Valuation, Profitability & More - Value Research
InspireMD Inc. (NSPR) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
InspireMD (NSPR) Drops 4.65% to $0.89 as Key Support at $0.85 Comes into FocusETF Creation Redemption - siam.in
Maxim Group Maintains InspireMD(NSPR.US) With Buy Rating, Maintains Target Price $3 - Moomoo
InspireMD (NSPR) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
InspireMD Q2 2026 Earnings: Revenue Misses $1.77 Million Estimate - Sci-Tech Today
Maxim Group Maintains InspireMD(NSPR.US) With Buy Rating, Cuts Target Price to $3 - Moomoo
NSPR Rallies After Hours On FDA Green Light for Key Stroke-Prevention Trial Despite Withdrawn Annual Guidance - Stocktwits
InspireMD total revenue down 0.4% to USD 1,771,000 in Q2 2026 - Medical Buyer
Form 8K InspireMD Inc For: 17 August By Investing.com - Investing.com South Africa
InspireMD Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
InspireMD Q2 revenue holds at $1.8 million - grafa.com
InspireMD Releases Q2 2026 Financial Results - AlphaStreet
InspireMD, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: InspireMD Q2 2026 revenue miss weighs on shares - Investing.com Nigeria
InspireMD Inc reports results for the quarter ended June 30Earnings Summary - TradingView
symbol__ Stock Quote Price and Forecast - CNN
InspireMD reports Q2 2026 revenue $1.77M, net loss $14.3M; cash & marketable securities $30.4M - TradingView
InspireMD Reports $1.77 Million Q2 Revenue and $14.32 Million Net Loss - Quiver Quantitative
InspireMD (NSPR) recall turns U.S. sales negative — and deepens quarterly loss - Stock Titan
InspireMD Q2 Operating Expenses USD 13.671 Mi - Moomoo
InspireMD Reports Second Quarter 2026 Financial Results - The Manila Times
InspireMD (NSPR) Surges 16.97% to $0.98, Pushing Toward Key ResistanceSentiment Shift - vinanet.vn
InspireMD, Inc. (NSPR) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
INSPIREMD Q2 2026 Earnings Preview: Recent $NSPR Insider Trading, Hedge Fund Activity, and More - Moomoo
InspireMD (NSPR) grows revenue 56% but flags going concern and Nasdaq risk - Stock Titan
InspireMD Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
InspireMD (NSPR) Dips 3.26% to $0.83, Pressing Against Key SupportVolatility Smirk - vinanet.vn
InspireMD (NSPR.US) is scheduled to release its financial report on August 17. - Moomoo
0.26%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):